Formulary Group work programme


The Group meets monthly on the third Tuesday of each month. The following list notes medicines that will be scheduled for review in the next three to four months. This list is indicative and may be subject to change.

Aflibercept (Eylea®) - SMC 1186/16 - Formulary Group Advice will be published by 4th January 2017. (Indication: in adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV)).

Cabazitaxel (Jevtana®) - SMC 735/11 - Formulary Group Advice will be published by 4th January 2017. (Indication: in combination with prednisone or prednisolone, for the treatment of adult patients with hormone refractory metastatic prostate cancer previously treated with at least 225mg/m2 (three cycles) of docetaxel and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1).

Cefuroxime (Aprokam®) - SMC 932/13 - Formulary Group Advice will be published by 4th January 2017. (Indication: antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery).

Everolimus (Afinitor®) - SMC 872/13 - Formulary Group Advice will be published by 4th January 2017. (Indication: for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor).

Guanfacine (Intuniv®) - SMC 1123/16 - Formulary Group Advice will be published by 4th January 2017. (Indication: treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective).

Migalastat (Galafold®) - SMC 1196/16Formulary Group Advice will be published by 4th January 2017. (Indication: for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation).

Rituximab (Mabthera®) - FG1 395/16 - Formulary Group Advice will be published by 4th January 2017. (Indication: Relapsing Nephrotic Syndrome, Membranous Nephropathy (Minimal Change Disease and FSGS)).

Tolvaptan (Jinarc®) - SMC 1114/15 Formulary Group Advice will be published by 4th January 2017. (Indication: to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease).

Publication schedule

This web page is updated monthly, within 7 working days of publication of Scottish Medicines Consortium advice.

END